Eduardo Castanon

List of Publications by Year
in descending order

30 papers	1,825 citations	623734 14 h-index	642732 23 g-index
31 all docs	31 docs citations	31 times ranked	2849 citing authors

#	Article	IF	Citations
1	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
2	Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy, 2021, 70, 221-232.	4.2	12
3	Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 2021, 11, 1353-1367.	9.4	197
4	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology, 2021, 18, 558-576.	27.6	202
5	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic antiâ€“PD-1 for patients with antiâ€“PD-1â€“refractory tumors. Science Translational Medicine, 2020, 12, .	12.4	51
6	Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings. European Journal of Cancer, 2020, 136, 159-168.	2.8	13
7	Does active smoking worsen Covid-19?. European Journal of Internal Medicine, 2020, 77, 129-131.	2.2	8
8	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652.	2.8	21
9	Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. OncoImmunology, 2020, 9, 1760676.	4.6	4
10	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS ONE, 2019, 14, e0215970.	2.5	3
11	Cytokines in clinical cancer immunotherapy. British Journal of Cancer, 2019, 120, 6-15.	6.4	720
12	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Safety, 2019, 42, 281-294.	3.2	69
13	International Symposium: Trailblazing in Cancer Immunotherapy, October 29â€“31, 2017, Pamplona, Spain. Cancer Immunology, Immunotherapy, 2018, 67, 1809-1813.	4.2	0
14	The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. Cancer Letters, 2017, 402, 43-51.	7.2	36
15	Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. European Respiratory Journal, 2017, 49, 1600282.	6.7	52
16	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). European Journal of Cancer, 2017, 84, 212-218.	2.8	132
17	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer, 2017, 20, 465-474.	5.3	20
18	A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. British Journal of Cancer, 2016, 114, 1191-1198.	6.4	14

#	Article	IF	Citations
19	Anti-PD1â€“Induced Pneumonitis: Capturing the Hidden Enemy. Clinical Cancer Research, 2016, 22, 5956-5958.	7.0	12
20	Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. Journal of Translational Medicine, 2015, 13, 257.	4.4	26
21	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers, 2015, 7, 556-573.	3.7	33
22	Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study. Journal of Clinical Oncology, 2015, 33, 465-471.	1.6	118
23	Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study.. Journal of Clinical Oncology, 2015, 33, 9617-9617.	1.6	0
24	Differential Tumor Expression of Inhibitor of Differentiation-1 in Prostate Cancer Patients With Extreme Clinical Phenotypes and Prognostic Implications. Clinical Genitourinary Cancer, 2014, 12, 87-93.	1.9	8
25	A nomogram for predicting serious complications in patients with solid tumors and apparently stable febrile neutropenia: Prospective data on 781 consecutive episodes from the FINITE study.. Journal of Clinical Oncology, 2014, 32, 165-165.	1.6	1
26	Preliminary results of preoperative FOLFOX chemotherapy for locally advanced colon cancer patients with therapeutic drug monitoring of 5-FU.. Journal of Clinical Oncology, 2014, 32, 579-579.	1.6	0
27	Oxaliplatin, irinotecan, and PK-adjusted 5-fluorouracil within a multidisciplinary approach in patients with locally advanced pancreatic cancer (LAPC): Preliminary results.. Journal of Clinical Oncology, 2014, 32, 356-356.	1.6	0
28	Familial clustering of prostate cancer (Pca) cases in a nonselected south European population (sEp).. Journal of Clinical Oncology, 2014, 32, 233-233.	1.6	0
29	Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. Journal of Translational Medicine, 2013, 11, 13.	4.4	38
30	Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.. Journal of Clinical Oncology, 2012, 30, 145-145.	1.6	0